Protocol 19-01: Canadian, Single Centre, Pilot, Open Label Study to Evaluate the Efficacy and Safety of the Bacterial Vaccine Uromune in Treating Recurrent Urinary Tract Infections in Women
Latest Information Update: 03 Jun 2024
At a glance
- Drugs Enterococcus-faecalis-FK23/escherichia-coli-vaccine/klebsiella-vaccine/proteus-vulgaris-inactivated-vaccine (Primary)
- Indications Urinary tract infections
- Focus Therapeutic Use
- Acronyms Protocol 19-01
Most Recent Events
- 29 May 2024 Status changed from active, no longer recruiting to discontinued due to increased Covid-related costs of clinical research and as per the available funding.
- 28 Jul 2022 Planned primary completion date changed from 31 Oct 2021 to 31 Oct 2022.
- 26 Oct 2021 Status changed from recruiting to active, no longer recruiting.